He has conquered COVID-19 for the time being, and now the CEO of BioNTech says he wants to turn his attention back to his first interest: cancer.
"We are cancer doctors," Sahin told CNN in an interview ahead of the meeting. "We are really passionate about that. What we want to accomplish is to provide really better treatments." They work best against blood-based cancers, Sahin noted. He is trying the approach against solid tumors. BioNTech is looking at a particular molecule active on cancer cells called claudin 6. "It is not expressed in healthy cells," Sahin said. "But it is activated and expressed in several types of cancers like testicular cancer, ovarian cancer, endometrial cancer, and the percentage of other tumors, a smaller percentage of stomach cancer, lung cancer and of some sorts of sarcomas," he added.
"This appears to be safe. We don't see toxicity. But we see a clinical activity. We see, even at the low dose, we are starting to see shrinkage of tumors."
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: CTVNews - 🏆 1. / 99 Read more »